NCT06932562View on ClinicalTrials.gov

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2036

Study Completion Date

December 31, 2036

Conditions
Multiple Myeloma
Interventions
DRUG

Linvoseltamab

Administered per the protocol

DRUG

Daratumumab

Administered per the protocol

DRUG

Lenalidomide

Administered per the protocol

DRUG

Dexamethasone

Administered per the protocol

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

European Myeloma Network B.V.

NETWORK

NCT06932562 - A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | Biotech Hunter | Biotech Hunter